Home > Envivo Pharmaceuticals Salary

Envivo Pharmaceuticals Salary

  • 90
  • 89
  • 86
Envivo Pharmaceuticals average salary is $42,000, median salary is $39,000 with a salary range from $30,000 to $57,000.
Envivo Pharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. Envivo Pharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
30,000
Average
42,000
Median
39,000
High
57,000
Total 3 Envivo Pharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Musical Director 57,000-57,000 New York, NY, 10001 2016 Envivo Pharmaceuticals Musical Director Salaries (3)
Envivo Pharmaceuticals New York, NY Salaries
Musical Director 39,000-39,000 WATERTOWN, MA, 02472 2014 Envivo Pharmaceuticals Musical Director Salaries (3)
Envivo Pharmaceuticals WATERTOWN, MA Salaries
Musical Director 30,000-30,000 New York, NY, 10001 2012 Envivo Pharmaceuticals Musical Director Salaries (3)
Envivo Pharmaceuticals New York, NY Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Envivo Pharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Envivo Pharmaceuticals Jobs
See more Envivo Pharmaceuticals Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Envivo Pharmaceuticals... Information
  • EnVivo Pharmaceuticals
  • Industry: BioTech/Drugs
  • City: Watertown, MA
  • EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders, currently focusing on Alzheimer¡¯s disease, Parkinson¡¯s disease, Huntington¡¯s disease, and Spinocerebellar ataxias. The company¡¯s lead programs include a Nicotinic Acetylcholine Receptor Agonist Program for Alzheimer¡¯s disease, a Histone Deacetylase (HDAC) Program for Huntington¡¯s disease and a Neuroprotection Program (EVPK-0003546) for Huntington¡¯s disease as well as other neurodegenerative indications.